학술논문

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Document Type
Article
Source
In Blood Advances 26 September 2023 7(18):5272-5280
Subject
Clinical Trials and Observations
Immunobiology and Immunotherapy
Lymphoid Neoplasia
Language
ISSN
2473-9529